The Treatment of Patients

The treatment of patients suffering from PD consistently better than those who received placebo. After eight weeks of starting treatment, 32 p. The percent of patients in the placebo group developed an improvement of one point on a scale to assess disability (Expanded Disability within Center [EDSS]), while this number percent at 65. Percent in the group that received treatment with MP.

Another controlled study of recently in the UK, compared with MPIV MP by mouth. Patients were treated MS ninety within four weeks after the start of the outbreak. Of these patients, 38 MPIV (1000 mg / day for 3 days) and 42 MP oral (48 mg / day for 7 days, then 24 mg / day for 7 days and 12 mg / day for 7 days). Thus, the cumulative dose of methyl mg 3000 in Group D and 588 mg oral group. The primary endpoint was the difference between the two groups with regard to improving the EDSS (at least one point) after four weeks. Was measured no significant difference from pre-primary endpoint, or other parameters at one time or another during the study.